Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 543064 | NSE Symbol : SUVENPHAR | ISIN : INE03QK01018 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
26-Sep-2024	12-Nov-2024	Quarterly Results	Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ending September 30 2024 Outcome of the Board Meeting (As per BSE Announcement Dated on 12/11/2024)
19-Sep-2024	19-Sep-2024	Change in Directors	Change in Directorate
02-Aug-2024	09-Aug-2024	Quarterly Results	Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Friday the 09th August 2024 at 01:00 p.m. IST at the Corporate Office 202 A-Wing Galaxy Towers Plot No.1 Hyderabad Knowledge City TSIIC Raidurg Hyderabad Telangana - 500081 of the Company to consider inter alia and approve the following matter(s): To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the first quarter ended June 30 2024 and other matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st July 2024 as per PIT Code of the Company. Trading window will be opened from 12th August 2024. Outcome of the Board Meeting Appointment of Company Secretary and Compliance Officer effective from September 03, 2024 (As per BSE Announcement Dated on 09/08/2024)
12-Jul-2024	12-Jul-2024	AGM	With reference to the above subject, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. July 12, 2024, approved the following along with other business matters. 1. Appointment of Statutory Auditors: 2. e-Annual General Meeting (AGM): a) Approved the Notice and Agenda for the 6th Annual General Meeting (AGM) of the Members of the Company scheduled to be held on Friday, the 09th day of August, 2024 at 4.30 p.m. through Video-Conferencing ('VC') or Other Audio Visual Means ('OAVM') b) Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Register of Member and Share Transfer Books of the Company will remain closed from August 07, 2024 to August 09, 2024 (both days inclusive) for the purpose of 6th Annual General Meeting of the Company. We request you to take this document on your records. The Board Meeting commenced at 02:30 p.m. and concluded at 03.45 p.m. Appointment of Walker Chandiok & Co LLP as Statutory auditors of the Company w.e.f 07 July 2024 subject to approval of members.
20-May-2024	30-May-2024	Accounts	Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Monday the 27th May 2024 at 05:30 p.m. IST at the Corporate Office 202 A-Wing Galaxy Towers Plot No.1 Hyderabad Knowledge City TSIIC Raidurg Hyderabad Telangana - 500081 of the Company to consider inter alia and approve the following matter(s): To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and year ended March 31 2024 and other matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st April 2024 as per PIT Code of the Company. Trading window will be opened from 30th May 2024. You are requested to take this notice on your record. Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Monday, the 27th May, 2024 at 05:30 p.m. IST at the Corporate Office, 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, Telangana - 500081 of the Company, to consider, inter alia, and approve the following matter(s): To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and year ended March 31, 2024 and other matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st April, 2024 as per PIT Code of the Company. Trading window will be opened from 30th May, 2024. You are requested to take this notice on your record. (As Per BSE Announcement Dated on 20.05.2024) The Board Meeting to be held on 27/05/2024 has been revised to 30/05/2024 Further to our letter dated May 20th, 2024, this is to inform you that the meeting of the Board of Directors of the Company scheduled to be held on May 27, 2024, at the Corporate Office, 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, Telangana - 500081 of the Company, inter alia, to consider and approve the Audited Standalone and Consolidated financial results of the Company for the fourth quarter and financial year ended March 31, 2024 has been postponed and rescheduled to Thursday May 30th 2024. We would also like to inform that the Earnings Conference Call, which was scheduled on Monday 27th May 2024, at 7.00 p.m. (IST), to discuss on the Company's Audited Financial Results, has also been postponed accordingly. The revised Earnings Conference Call details will be notified through separate communication. (As Per BSE Announcement Dated on 21/05/2024) Outcome of the Board Meeting Outcome of the Board Meeting (As Per BSE Announcement Dated on 30.05.2024)
29-Feb-2024	29-Feb-2024	Scheme of Amalgamation	Outcome of the Board Meeting Outcome of the Board Meeting started at 17.30 and ended at 18.30
29-Jan-2024	05-Feb-2024	Quarterly Results	Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2024 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Monday the 05th February 2024 at 04:00 p.m. IST at the Corporate Office 202 A-Wing Galaxy Towers Plot No.1 Hyderabad Knowledge City TSIIC Raidurg Hyderabad Telangana - 500081 of the Company to consider inter alia and To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the third quarter and nine months ended December 31 2023 and other matters. unaudited standalone and consolidated financial results for quarter and nine months ended December 31, 2023 , Limited Review Reports, Press Release and Investors Presentation. (As Per BSE Announcement dated on 05.02.2024)
21-Dec-2023	21-Dec-2023	Employee Stock Option	Pursunat to the recommendations of NRC and approval of Audit Committee, the Board has considered and approved the appointment of Mr. Himanshu Agarwal as the Chief Financial Officer and Key Managerial Personnel of the Company w.e.f January 2, 2024 in place of Mr. Subba Rao Parupalli Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ('Listing Regulations'), we wish to inform that the Board of Directors of the Company, at its meeting held today i.e., December 21, 2023, inter alia, approved the following along with other business matters
02-Nov-2023	09-Nov-2023	Quarterly Results	Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the second quarter and half-year ended September 30 2023 and other matters. Closure of Register of Members for the purpose of 5th Annual General Meeting of the Company Appointment of Directors Un- Audited Standalone and consolidated FInancial Results prepared under INA AS for quarter and half year ended September 30, 2023 (As Per BSE Announcement dated on 09.11.2023)
29-Sep-2023	29-Sep-2023	Change in Directors	Outcome of the board meeting - Intimation of change in control of the company and change in directors of the company Outcome of the board meeting - Intimation of change in control of the company and change in directors of the company This is in furtherance to the letter dated 26 December 2022 pursuant to which it was informed that inter-alia a promoter of the Company i.e. Jasti Property and Equity Holdings Private Limited (in its capacity as sole trustee of Jasti Family Trust) (Seller) has executed a share purchase agreement with Berhyanda Limited (Acquirer) a Cyprus based company on 26 December 2022 (Share Purchase Agreement).
01-Aug-2023	08-Aug-2023	Quarterly Results	Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2023 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Tuesday the 8th August 2023 at 3:00 p.m. at the Registered Office SDE Serene Chambers 3rd Floor Road No 5 Banjara Hills Hyderabad - 500034 of the Company to consider inter alia and approve the following matter(s): To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the first quarter ended June 30 2023 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st July 2023 as per PIT Code of the Company. Trading window will be opened from 11th August 2023. we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. August 8, 2023, has taken on record and apporved the attached Un-audited Standalone and Conslidated Financial Results of the Company prepared under IND AS for the quarter ended 30th June, 2023 along with Limited Reveiw Reports of the Staturoty Auditors. (As Per BSE Announcement dated on 08.08.2023)
18-May-2023	25-May-2023	Accounts	Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2023 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Thursday the 25th May 2023 at 11:30 a.m. at the Registered Office SDE Serene Chambers 3rd Floor Road No 5 Banjara Hills Hyderabad - 500034 of the Company to consider inter alia and approve the following matter(s): To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ended March 31 2023 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st April 2023 as per PIT Code of the Company. Trading window will be opened from 29th May 2023. You are requested to take this notice on your record. With reference to the above subject, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. May 25, 2023, has taken on record and approved the attached Audited Standalone and Consolidated Financial Statements of the Company prepared under IND AS for the quarter and year ending 31st March, 2023 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Auditors' Reports of the Statutory Auditors. Further, we are enclosing herewith the following documents: 1) Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2023 along with Statement of Assets and Liabilities, Profit & Loss account and Cash Flow Statement. 2) Auditor's Reports on the financial results as mentioned above 3) Declaration in respect of Audit Reports with unmodified opinion and 4) Earnings Presentation of our company to investors (As per BSE Announcement Dated on 25/05/2023)
30-Jan-2023	06-Feb-2023	Quarterly Results	Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2023 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Monday the February 6 2023 at 11:30 a.m. at the Registered Office SDE Serene Chambers 3rd Floor Road No. 5 Banjara Hills Hyderabad - 500034 of the Company to consider inter alia and approve the following matter(s): To consider and approve the Un-Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the third quarter and nine months ended December 31 2022 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st January 2023 as per PIT Code of the Company. Trading window will be opened from 10th February 2023. You are requested to take this notice on your record. With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. February 6, 2023, has taken on record and approved the Un-Audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter and nine months ended 31st December, 2022. We are enclosing herewith the following documents: 1) Un-audited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2022 2) Limited Review Reports on the financial results as mentioned above and 3) Earnings Presentation of our company to investors We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:55 P.M. This is for your information and record. (As Per BSE Announcement dated on 06.02.2023)
01-Nov-2022	08-Nov-2022	Quarterly Results	Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2022 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Tuesday the November 8 2022 at 11:30 a.m. at the Registered Office SDE Serene Chambers 3rd Floor Road No. 5 Banjara Hills Hyderabad - 500034 of the Company to consider inter alia and approve the following matter(s): To consider and approve the Un-Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the second quarter and half-year ending September 30 2022 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st October 2022 as per PIT Code of the Company. Trading window will be opened from 12th November 2022. With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. November 08, 2022, has taken on record and approved the Un-Audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter and half-year ended 30th September, 2022. We are enclosing herewith the following documents: 1) Un-audited Standalone and Consolidated Financial Results for the quarter and half-year ended 30th September, 2022 2) Limited Review Reports on the financial results as mentioned above and 3) Earnings Presentation of our company to investors We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:30 P.M. This is for your information and record. (As Per BSE Announcement Dated on 08.11.2022)
29-Aug-2022	02-Sep-2022	Interim Dividend	Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2022 inter alia to consider and approve With reference to above subject pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that a Meeting of the Board of Directors of the Company will be held on Friday the September 02 2022 at 12:30 p.m. at the Registered Office SDE Serene Chambers 3rd Floor Road No 5 Banjara Hills Hyderabad - 500034 of the Company to consider inter alia and approve the following matter(s): 1) To consider declaration of Interim Dividend for the financial year 2022-23 and related matters etc. and 2) Advance intimation under regulation 42: The Record Date for the purpose of payment of interim dividend to eligible shareholders would be September 12 2022 if considered and approved by the Board. Please further note that TRADING WINDOW for dealing in the securities of the company will be closed from August 30 2022 as per PIT Code of the Company. Trading window will be opened from September 05 2022. With reference to the above subject, the Board of Directors of the company, at its meeting held today i.e. September 02, 2022, approved the following matters. Interim Dividend a) The Board has declared an Interim Dividend of Rs.1.00 per equity share (100% of face value of Rs.1.00 each) and special dividend of Rs. 5.00 per equity share (500% of face value of Rs.1.00), totaling to Rs. 6.00 per equity share (600% of face value of Rs. 1.00 each) for the financial year 2022-23. b) The Board has approved the Record Date i.e., September 12, 2022 notified earlier by the Company for the purpose of payment of dividend to the eligible shareholders. c) The above said dividend will be paid on and from September 20, 2022. The Board Meeting commenced at 12:30 P.M. and concluded at 1:20 P.M. With reference to the above subject, the Board of Directors of the company, at its meeting held today i.e. September 02, 2022, approved the following matters. Interim Dividend a) The Board has declared an Interim Dividend of Rs.1.00 per equity share (100% of face value of Rs.1.00 each) and special dividend of Rs. 5.00 per equity share (500% of face value of Rs.1.00), totaling to Rs. 6.00 per equity share (600% of face value of Rs. 1.00 each) for the financial year 2022-23. b) The Board has approved the Record Date i.e., September 12, 2022 notified earlier by the Company for the purpose of payment of dividend to the eligible shareholders. c) The above said dividend will be paid on and from September 20, 2022. The Board Meeting commenced at 12:30 P.M. and concluded at 1:20 P.M. This is for your information and record. (As Per BSE Announcement Dated on 02.09.2022)

1 2 3

LOGIN HERE

Suven Pharmaceuticals Ltd

Board Meeting